AOD-9604 in Kardos — Fat Loss Peptide Research Guide
AOD-9604 research guide for Kardos. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers seeking out AOD-9604 in Kardos rapidly learn that local retail options are all but absent from local stores. What this means for Kardos researchers is that geography is secondary to your ability to assess COA data — and those quality checks are available to every researcher. Vendors worth sourcing from openly share batch-matched Certificates of Analysis showing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. This guide gives Kardos researchers the practical tools to assess vendor quality rigorously and source research-grade AOD-9604 with confidence.
Understanding AOD-9604 — Biology & Evidence
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Kardos studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source AOD-9604 — Vendor Guide
Quality AOD-9604 sourcing begins with a straightforward question: does this vendor publish batch-specific COAs proactively? Those who make this data freely available are demonstrating research-grade standards. A COA for AOD-9604 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. For Kardos researchers evaluating new suppliers: a test quantity before committing to research volumes before placing larger orders is standard practice in the community. Keep lyophilised AOD-9604 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order AOD-9604 — ships to Kardos
COA-verified · International tracking · Research grade
AOD-9604 operates outside approved pharmaceutical regulation — researchers should understand that the safety data available for AOD-9604 is based on research literature rather than clinical trials. Lyophilised AOD-9604 should be stored frozen (−20°C) immediately upon receipt; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. Endotoxin testing in the AOD-9604 COA is non-negotiable — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at minute levels, and no cost saving makes omitting this acceptable. For any individual considering AOD-9604 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
